COMP <GO>
AKBA vs LLY // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Akebia Therapeutics Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: AKBA 3
— LLY 8
■ METRIC PARITY
LAST: $0.71 (+0.27%) • MKT CAP: $195.8M
options-implied-move
—
LAST: $1,410.99 (-0.46%) • MKT CAP: $1.33T
options-implied-move
6.81%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AKBA VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AKBA | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 83.30% | 83.64% | -0.34 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 85.00% | 32.36% | +52.64 | AKBA | /roic <GO> |
| EV/EBITDA & P/E Valuation | 4.3x | 36.4x | -32.09 | AKBA | /valuation <GO> |
| Free Cash Flow Yield | — | 2.30% | — | TIE | /fcf-yield <GO> |
| Operating Margin | 9.90% | 40.21% | -30.31 | LLY | /operating-margins <GO> |
| Net Profit Margin | -2.20% | 31.90% | -34.10 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 47.50% | 45.51% | +1.99 | AKBA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 9.29 | -9.09 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 9/9 | -2.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | — | 6.81% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.2 | 71.0 | -25.80 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.51 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 30.6x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $195.8M | $1.33T | -$1.33T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AKBA REV | LLY REV | AKBA GROSS % | LLY GROSS % | AKBA FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $236.2M | $65.18B | 83.3% | 83.0% | $67.7M | $16.81B |
| FY 2024 | $160.2M | $45.04B | 60.6% | 81.3% | -$40.7M | $8.82B |
| FY 2023 | $194.6M | $34.12B | — | 79.3% | -$23.4M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AKBA // BETA —
LLY // BETA 0.51